← Back to headlines
Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics
Bioventus has outlined a 2026 sales target of $600M–$610M, driven by accelerated investment in PNS, PRP, and ultrasonics technologies.
5 Mar, 15:26 — 5 Mar, 15:26
Sources
Showing 1 of 1 sources
